# EDGAR Filing Document

**Accession Number:** 0000025743
**File Stem:** 0001213900-25-105183
**Filing Date:** 2025-11
**Character Count:** 137251
**Document Hash:** 1c94991ded38a7609195adf903d71b94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-105183.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001213900-25-105183

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 27

**CONFORMED PERIOD OF REPORT**: 20251215

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TherapeuticsMD, Inc.
- **CENTRAL INDEX KEY:** 0000025743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870233535
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-00100
- **FILM NUMBER:** 251443958

**BUSINESS ADDRESS:**
- **STREET 1:** 951 YAMATO ROAD, SUITE 220
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 561-961-1900

**MAIL ADDRESS:**
- **STREET 1:** 951 YAMATO ROAD, SUITE 220
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMHN, Inc.
- **DATE OF NAME CHANGE:** 20090930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CROFF ENTERPRISES INC
- **DATE OF NAME CHANGE:** 19970915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CROFF OIL CO
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

 **UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549**

**________________________**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;)**

**________________________**

<u> Filed by the Registrant </u>   <u> ☒ </u>   <u> Filed by a party other than the Registrant </u>   <u> ☐ </u>

Check the appropriate box:

 ☐ Preliminary Proxy Statement

 ☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a**-6**(e)(2))**

 ☒ Definitive Proxy Statement

 ☐ Definitive Additional Materials

 ☐ Soliciting Material under §240.14a-12

**TherapeuticsMD, Inc.**

**(Name of Registrant as Specified in its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

Payment of Filing Fee (Check all boxes that apply):

<u> ☒ </u>   <u> No fee required. </u> <br> <u> ☐ </u>   <u> Fee paid previously with preliminary materials. </u> <br> <u> ☐ </u>   <u> Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. </u>

------

[**Table of Contents**](#TOC001)

**THERAPEUTICSMD, INC. NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 15, 2025**

An Annual Meeting of Stockholders of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), will be held at 8:00 a.m., Eastern Time, on December 15, 2025. The annual meeting will be a virtual meeting conducted solely online via live webcast and can be attended by visiting www.proxydocs.com/TXMD.

The Annual Meeting of Stockholders will be held for the following purposes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024 ("say-on-pay");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers ("say-on-frequency");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP ("Berkowitz Pollack Brant"), an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;To transact such other business as may properly come before the meeting or any adjournment thereof.

The foregoing items of business are more fully described in the proxy statement accompanying this notice.

Only stockholders of record at the close of business on October 20, 2025 are entitled to notice of and to vote at the meeting. All stockholders are cordially invited to attend the meeting and vote virtually.

In accordance with rules adopted by the Securities and Exchange Commission that allow companies to furnish their proxy materials over the Internet, we are mailing a Notice of Internet Availability of Proxy Materials, instead of a paper copy of our proxy statement and our 2024 Annual Report, to most of our stockholders. The Notice of Internet Availability of Proxy Materials contains instructions on how to access those documents and vote over the Internet. The Notice of Internet Availability of Proxy Materials also contains instructions on how to request a paper copy of our proxy materials, including our proxy statement, our 2024 Annual Report, and a proxy card. We believe this process will allow us to provide our stockholders the information they need in a more timely manner, while reducing the environmental impact and lowering our costs of printing and delivering the proxy materials.

Whether or not you plan to virtually attend, it is important that your shares be represented and voted at the annual meeting. You may vote your shares over the Internet as described in the Notice of Internet Availability of Proxy Materials. As an alternative, if you received a paper copy of the proxy materials by mail, you can also vote by mail by following the instructions on the proxy card. You may also vote by telephone as described in your proxy card. Even if you have submitted a proxy before the meeting, you may still attend the meeting, revoke your proxy and vote virtually. We appreciate your continued support of our Company.

---

| |
|:---|
|  By Order of the Board of Directors, |
|  ![](tmarlan_sig.jpg) |
|  MARLAN D. WALKER |
|  Chief Executive Officer |

---

Boca Raton, Florida

November 3, 2025

------

[**Table of Contents**](#TOC001)

### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  [Proxy Summary](#T999901) | **3** |
|  [Voting and Other Matters](#T999902) | **4** |
|  [**Proposal One:** Election of Directors](#T999903) | **7** |
| &nbsp;&nbsp;&nbsp; [Nominees](#T999904) | 7 |
| &nbsp;&nbsp;&nbsp; [Executive Officers](#T999905) | 10 |
|  [Corporate Governance](#T999906) | **11** |
| &nbsp;&nbsp;&nbsp; [Director Independence](#T999907) | 11 |
| &nbsp;&nbsp;&nbsp; [Committee Charters, Corporate Governance, and Code of Ethics](#T999908) | 11 |
| &nbsp;&nbsp;&nbsp; [Executive Sessions](#T999909) | 11 |
| &nbsp;&nbsp;&nbsp; [Board Committees](#T999910) | 11 |
| &nbsp;&nbsp;&nbsp; [Board's Role in Risk Oversight](#T999911) | 13 |
| &nbsp;&nbsp;&nbsp; [Board Composition](#T999912) | 13 |
| &nbsp;&nbsp;&nbsp; [Board Leadership Structure](#T999913) | 14 |
| &nbsp;&nbsp;&nbsp; [Compensation Committee Interlocks and Insider Participation](#T999914) | 14 |
| &nbsp;&nbsp;&nbsp; [Compensation Recovery Policy](#T999915) | 14 |
| &nbsp;&nbsp;&nbsp; [Anti-Hedging and Anti-Pledging Policy](#T999916) | 14 |
| &nbsp;&nbsp;&nbsp; [Board and Committee Meetings](#T999917) | 15 |
| &nbsp;&nbsp;&nbsp; [Annual Meeting Attendance](#T999918) | 15 |
| &nbsp;&nbsp;&nbsp; [Communications with Directors](#T999919) | 15 |
|  [Executive Compensation](#T999920) | **16** |
| &nbsp;&nbsp;&nbsp; [Fiscal Year 2024 Summary Compensation Table](#T999921) | 17 |
| &nbsp;&nbsp;&nbsp; [Outstanding Equity Awards at Fiscal Year-End 2024](#T999922) | 18 |
| &nbsp;&nbsp;&nbsp; [Post-Employment Compensation](#T999923) | 19 |
| &nbsp;&nbsp;&nbsp; [Employment Agreement](#T999924) | 19 |
| &nbsp;&nbsp;&nbsp; [Master Services Agreement](#T999925) | 19 |
| &nbsp;&nbsp;&nbsp; [Potential Payments Upon Termination or Change in Control](#T999926) | 20 |
| &nbsp;&nbsp;&nbsp; [Nonqualified Defined Contribution and Nonqualified Deferred Compensation](#T999927) | 21 |
| &nbsp;&nbsp;&nbsp; [Limitation of Directors' Liability; Indemnification of Directors, Officers, Employees, and Agents](#T999928) | 21 |
| &nbsp;&nbsp;&nbsp; [Pay vs. Performance Comparison](#T999929) | 22 |
|  [Equity Compensation Plan Information](#T999930) | **26** |
|  [Certain Transactions and Relationships](#T999931) | **27** |
|  [Director Compensation](#T999932) | **28** |
|  [Report of the Audit Committee](#T999933) | **29** |
|  [Delinquent Section 16(A) Reports](#T999934) | **30** |
|  [Security Ownership of Principal Stockholders, Directors, and Officers](#T999935) | **31** |
|  [**Proposal Two:** Advisory Vote on Executive Compensation ("Say-on-Pay")](#T999936) | **32** |
|  [**Proposal Three:** Advisory Vote on Determining the Frequency of "Say-on-Pay" ("Say-on-Frequency")](#T999937) | **33** |
|  [**Proposal Four:** Ratification of Appointment of Independent Auditor](#T999942) | **34** |
|  [**Proposal Five:** Approval of an Amendment to the Amended and Restated Articles of Incorporation, as Amended](#T1982) | **36** |
|  [Deadline For Receipt of Stockholder Proposals](#T999938) | **38** |
|  [Householding of Proxy Materials](#T999939) | **38** |
|  [Other Matters](#T999940) | **38** |
|  [Where You Can Find Additional Information and Incorporation by Reference](#T999941) | **39** |
|  [**Appendix A:** Amendment to Amended and Restated Articles of Incorporation, as Amended](#T1983) | **A-1** |

---

&nbsp;&nbsp;&nbsp;&nbsp; 2<br>

------

[**Table of Contents**](#TOC001)

 **PROXY SUMMARY**<br>

This summary highlights information contained elsewhere in the Proxy Statement. This summary does not contain all of the information you should consider. Please read the entire Proxy Statement carefully before voting.

**2025 Annual Meeting of Stockholders**<br>

---

| | | |
|:---|:---|:---|
|  ![](timage_001.jpg) | ![](timage_002.jpg) | ![](timage_003.jpg) |
|  **Date and Time:** December 15, 2025 <br>8:00 am Eastern Time | **Place:** <br> Online via live webcast <br>at: <br>www.proxydocs.com/TXMD | **Record Date:** <br>October 20, 2025 |

---

**Items of Business:**<br>

• To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified;

• To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024 ("say-on-pay");

• To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers ("say-on-frequency");

• To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP ("Berkowitz Pollack Brant"), an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025;

• To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares; and

• To transact such other business as may properly come before the meeting or any adjournment thereof.

&nbsp;&nbsp;&nbsp;&nbsp; 3 <br>

------

[**Table of Contents**](#TOC001)

**THERAPEUTICSMD, INC. 951 Yamato Road, Suite 220 Boca Raton, Florida 33431**

### PROXY STATEMENT

### VOTING AND OTHER MATTERS

#### General
The accompanying proxy is solicited on behalf of TherapeuticsMD, Inc., a Nevada corporation, by our Board of Directors for use at our Annual Meeting of Stockholders to be held at 8:00 a.m., Eastern Time, on Monday, December 15, 2025, or at any adjournment thereof, for the purposes set forth in this proxy statement and in the accompanying notice. The annual meeting will be a virtual meeting conducted solely online via live webcast and can be attended by visiting www.proxydocs.com/TXMD. In accordance with rules adopted by the Securities and Exchange Commission (the "SEC") that allow companies to furnish their proxy materials over the Internet, we are mailing a Notice of Internet Availability of Proxy Materials, instead of a paper copy of our proxy statement and our 2024 Annual Report, to most of our stockholders. The Notice of Internet Availability of Proxy Materials contains instructions on how to access those documents and vote over the Internet. The Notice of Internet Availability of Proxy Materials also contains instructions on how to request a paper copy of our proxy materials, including our proxy statement, our 2024 Annual Report, and a proxy card. We believe this process will allow us to provide our stockholders the information they need in a more timely manner, while reducing the environmental impact and lowering our costs of printing and delivering the proxy materials.

These proxy solicitation materials are anticipated to first be distributed on or about November 3, 2025 to all stockholders entitled to vote at the meeting.

**Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on December 15, 2025.** These proxy materials, which include the notice of annual meeting, this proxy statement and our 2024 Annual Report, are available at www.proxydocs.com/TXMD.

We encourage you to access the meeting 15 minutes prior to the start time leaving ample time for the check in and to ensure that you can hear audio prior to the meeting. If you encounter any difficulties accessing the meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual annual meeting page for assistance. Technical support will be available 15 minutes prior to the start of the meeting.

#### Record Date and Outstanding Shares
Stockholders of record at the close of business on October 20, 2025 (the "Record Date") are entitled to notice of and to vote at the meeting. On the Record Date, there were issued and outstanding 11,574,362 shares of our common stock. Each holder of common stock voting at the meeting, either virtually or by proxy, may cast one vote per share of common stock held on all matters to be voted on at the meeting.

If, at the close of business on October 20, 2025, your shares were registered directly in your name with our transfer agent, Computershare Trust Company, N.A. ("Computershare"), then you are a stockholder of record. As a stockholder of record, you may vote virtually at the meeting. However, whether or not you plan to attend the meeting, we urge you to vote by proxy over the Internet or by telephone as instructed on the Notice of Internet Availability of Proxy Materials, or to fill out and return the proxy card to ensure your vote is counted. Even if you have submitted a proxy before the meeting, you may still attend the meeting, revoke your proxy and vote virtually.

If, at the close of business on October 20, 2025, your shares were held in an account at a brokerage firm, bank, or similar organization, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the meeting. As a beneficial owner, you have the right to direct your broker, bank, or other nominee on how to vote the shares in your account. You should have received voting instructions with these proxy materials from that organization rather than from us. You should follow the instructions provided by that organization to submit your vote. You are also invited to attend the meeting virtually. However, since you are not the stockholder of record, you may not vote your shares virtually at the meeting unless you obtain a legal proxy or a valid control number from the broker, bank, or other nominee that holds your shares giving you the right to vote the shares at the meeting.

&nbsp;&nbsp;&nbsp;&nbsp; 4<br>

------

[**Table of Contents**](#TOC001)

#### Quorum
The presence, virtually or by proxy, of the holders of a majority of the total number of shares entitled to vote constitutes a quorum for the transaction of business at the meeting.

#### Required Votes
Assuming that a quorum is present, the four persons receiving the largest number of "for" votes of our common stock present virtually or by proxy at the meeting and entitled to vote (a plurality) will be elected directors. Stockholders do not have the right to cumulate their votes in the election of directors. Our plurality voting requirement for the election of directors is also subject to a majority voting policy as part of our Corporate Governance Guidelines. The majority voting policy is applicable solely to uncontested elections, which are those elections in which the number of nominees for election is less than or equal to the number of directors to be elected. Under the majority voting policy, any nominee for director who receives more "withhold" votes than "for" votes in an uncontested election must submit a written offer to resign as director. Any such resignation will be reviewed by the independent members of our Board of Directors and, within 90 days after the election, the independent members of our Board of Directors will determine whether to accept, reject or take other appropriate action with respect to, the resignation, in furtherance of the best interests of TherapeuticsMD and our stockholders.

Assuming that a quorum is present, the affirmative vote of a majority of shares entitled to vote on the matter and represented either in person virtually or by proxy will be required to ratify the appointment of Berkowitz Pollack Brant as the independent auditor of our Company for the fiscal year ending December 31, 2025 and to approve the amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, from 32,000,000 shares to 640,000,000 shares (the "Charter Amendment"). The advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2024 ("say-on-pay") and the advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers ("say-on-frequency") are non-binding, but our Board of Directors and the Compensation Committee of our Board of Directors (the "Compensation Committee") will consider the input of stockholders based on a majority of shares entitled to vote on the matter and represented either in person virtually or by proxy for the say-on-pay proposal and the say-on-frequency proposal alternative that receives the most votes.

Votes present by proxy or in person virtually at the meeting will be tabulated by the election inspector appointed for the meeting who will determine whether a quorum is present. The election inspector will treat abstentions as shares that are present and entitled to vote for purposes of determining the presence of a quorum and will be treated as votes against a proposal for purposes of determining the approval of any matter submitted to the stockholders for a vote. If a brokerage firm, bank, or similar organization indicates on the proxy that it does not have discretionary authority as to certain shares to vote on a particular matter, those shares will be counted towards the quorum requirement but will not be considered as present and entitled to vote with respect to that matter (*i.e*., they will have no effect).

#### Voting of Proxies
When a proxy is properly executed and returned, the shares it represents will be voted at the meeting as directed. If no specification is indicated, the shares will be voted (1) "for" the election of each of the four nominees for director set forth in this proxy statement, (2) "for" the approval of the compensation of our named executive officers for the fiscal year ended December 31, 2024, (3) "one year" on the proposal to determine the frequency of say-on-pay; (4) "for" the ratification of the appointment of Berkowitz Pollack Brant, an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025, (5) "for" the approval of the Charter Amendment, and (6) as the persons specified in the proxy deem advisable on such other matters as may come before the meeting.

#### Broker Non-Votes and Abstentions
Brokers, banks, or other nominees that hold shares of common stock in "street name" for a beneficial owner of those shares typically have the authority to vote in their discretion if permitted by the stock exchange or other organization of which they are members. Brokers, banks, and other nominees are permitted to vote the beneficial owner's proxy in their own discretion as to certain "routine" proposals when they have not received instructions from the beneficial owner, such as the ratification of the appointment of Berkowitz Pollack Brant as the independent auditor of our Company for the fiscal year ending December 31, 2025 and the Charter Amendment. If a broker, bank, or other nominee votes such "uninstructed" shares for or against a "routine" proposal, those shares will be counted towards determining whether or not a quorum is present and are considered entitled to vote on the "routine" proposals. However, where a proposal is "non-routine," a broker, bank, or other nominee is not permitted to exercise its voting discretion on that proposal without specific instructions from the beneficial owner. These non-voted shares are

&nbsp;&nbsp;&nbsp;&nbsp; 5 <br>

------

[**Table of Contents**](#TOC001)

referred to as "broker non-votes" when the nominee has voted on other non-routine matters with authorization or voted on routine matters. These shares will be counted towards determining whether or not a quorum is present but will not be considered entitled to vote on the "non-routine" proposals.

**Please note that brokers, banks, and other nominees may not use discretionary authority to vote shares on the election of directors, the approval of the compensation of our named executive officers or the say**-on-frequency **proposal if they have not received specific instructions from their clients. For your vote to be counted in the above, you now will need to communicate your voting decisions to your broker, bank, or other nominee before the date of the meeting.**

As provided in our bylaws, as amended, except as otherwise provided by law, or our Amended and Restated Articles of Incorporation, as amended, a majority of the shares entitled to vote on the matter and represented either in person (virtually for this year's annual meeting) or by proxy at the meeting in which a quorum is present shall be act of the stockholders. Therefore, for matters other than the election of our directors, which requires a plurality vote subject to the majority voting policy in our Corporate Governance Guidelines, the number of votes "for" a proposal must exceed the number of votes "against" that proposal. For all matters other than the election of our directors, if a stockholder votes to "abstain," it will have the same effect as a vote "against" that proposal. Because broker non-votes do not represent shares entitled to vote on a proposal, broker non-votes will have no effect on the proposal to elect directors, the approval of the compensation of our named executive officers, the say-on-frequency proposal, or the Charter Amendment, as each proposal is determined by reference to the shares present or represented by proxy and entitled to vote. Because the proposal to ratify the appointment of Berkowitz Pollack Brant as the independent auditor of our Company for the fiscal year ending December 31, 2025 and the Charter Amendment are "routine" proposals, broker non-votes are not expected to occur with respect to these proposals. Accordingly, if no vote is specified on the proxy and in the absence of directions to the contrary, the shares will be voted "FOR" the proposal to ratify the appointment of Berkowitz Pollack Brant as the independent auditor of our Company for the fiscal year ending December 31, 2025 and "FOR" the Charter Amendment.

#### Revocability of Proxies
Any stockholder giving a proxy may revoke the proxy at any time before its use by furnishing to us either a written notice of revocation or a duly executed proxy bearing a later date, or by attending the meeting and voting virtually. Attendance at the meeting will not cause your previously granted proxy to be revoked unless you specifically so request.

#### Election Inspector
Votes cast by proxy or virtually at the meeting will be tabulated by the election inspector appointed for the meeting, who will determine whether a quorum is present. The election inspector will treat broker non-votes and abstentions as shares that are present and entitled to vote for purposes of determining the presence of a quorum, and as described in the "Broker Non-Votes and Abstentions" section of this proxy statement for purposes of determining the approval of any matter submitted to the stockholders for a vote.

#### Solicitation
We will bear the cost of this solicitation. We have engaged Innisfree M&A Incorporated ("Innisfree") to assist in the solicitation of proxies for the annual meeting. We have agreed to pay Innisfree a fee of $25,000, reimburse Innisfree for certain expenses, and indemnify Innisfree under certain circumstances. In addition, we may reimburse brokerage firms and other persons representing beneficial owners of shares for expenses incurred in forwarding solicitation materials to such beneficial owners. Proxies also may be solicited by certain of our directors and officers, personally, by telephone, e-mail or by other means of communication, without additional compensation.

#### Submitting a Question or Making a Comment During the Meeting
If you want to submit a question or make a comment during the meeting, log into the virtual meeting platform at www.proxydocs.com/TXMD, type your question into the "Q&A" field, and click "Submit." Questions and comments submitted via the virtual meeting platform that are pertinent to meeting matters will be addressed during the meeting. Questions and comments that are not pertinent to meeting matters or that are not addressed during the meeting due to time constraints will be addressed after the meeting. Consistent with our approach when meetings are held in person, questions or comments that are not related to the proposals under discussion, are about personal concerns not shared by stockholders generally, or use blatantly offensive language may be ruled out of order.

&nbsp;&nbsp;&nbsp;&nbsp; 6<br>

------

[**Table of Contents**](#TOC001)

### Proposal One

### Election of Directors
**Nominees**<br>

Our Amended and Restated Articles of Incorporation and bylaws, each as amended, provide that the number of directors shall be fixed from time to time by resolution of our Board of Directors. Presently, the number of directors is fixed at four. Our bylaws, as amended, provide that all directors are elected at each annual meeting of our stockholders for a term of one year and hold office until their successors are elected and qualified.

A board of the four directors named in this proxy statement is to be elected at this meeting. Unless otherwise instructed, the proxy holders will vote the proxies received by them "for" each of the nominees named below. All of the nominees currently are directors of our Company. In the event that any nominee is unable or declines to serve as a director at the time of the meeting, the proxies will be voted for any nominee designated by our current Board of Directors to fill the vacancy. It is not expected that any nominee will be unable or will decline to serve as a director.

 **THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS <br>A VOTE "FOR" THE NOMINEES LISTED BELOW.**<br>

&nbsp;&nbsp;&nbsp;&nbsp; 7 <br>

------

[**Table of Contents**](#TOC001)

---

| | |
|:---|:---|
|  **TOMMY G. THOMPSON**<br> **Chairman of the Board**<br> **Director Since: 2012**<br> **Age: 83**<br> **Committee: Audit** | **Biographical Information**<br> Tommy G. Thompson has served as a director of our company since May 2012 and as the Chairman of the Board of Directors since March 2024. He previously served as the Chairman of the Board of Directors from May 2012 until September 2022 and as Executive Chairman of the Board from September 2022 until March 2024. From July 2020 until March 2022, Secretary Thompson served as the Interim President of the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare access across all segments of society. As the former Secretary of the U.S. Department of Health & Human Services, or HHS, from February 2001 to January 2005, Secretary Thompson served as the nation's leading advocate for the health and welfare of all Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer & Feld LLP, or Akin Gump, from March 2005 to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the Deloitte Center for Health Solutions, a healthcare consulting company, from March 2005 to May 2009. At the Deloitte Center for Health Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a non-profit organization focused on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for United Therapeutics Corporation [NASDAQ: UTHR] and Healthpeak Properties, Inc. (f/k/a Physicians Realty Trust) [NYSE: DOC]. Secretary Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February 2020, Centene Corporation [NYSE: CNC] from April 2005 to January 2022 and Scilex Holding Company [NASDAQ: SCLX] from 2022 to 2023, and has historically served on the boards of directors of other public companies.<br> **Key Qualifications and Experience** <br> We believe Secretary Thompson's experience in public service and on the boards of directors of numerous public companies, particularly his services and knowledge related to the healthcare industry as a whole, makes him well suited to serve on our Board of Directors. Secretary Thompson received both his B.S. and J.D. from the University of Wisconsin-Madison. |
|  **COOPER C. COLLINS**<br> **Director Since: 2012**<br> **Age: 46**<br> **Committees: Audit**<br> **Compensation** | **Biographical Information** <br> Cooper C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX], or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department.<br> **Key Qualifications and Experience** <br> We believe Mr. Collins' specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr. Collins received a B.A. from Nicholls State University, where he later received an M.B.A. |

---

&nbsp;&nbsp;&nbsp;&nbsp; 8<br>

------

[**Table of Contents**](#TOC001)

---

| | |
|:---|:---|
|  **GAIL K. NAUGHTON, PH.D.**<br> **Director Since: 2020** <br> **Age: 69** <br> **Committee:** <br> **Compensation** | **Biographical Information**<br> Gail K. Naughton, Ph.D. has served as a director of our company since March 2020. Dr. Naughton has served as the Chief Scientific Officer and Chief Business Development Officer of Histogen, a company she founded which is focused on the development of novel solutions based on the products of cells grown under simulated embryonic conditions, since April 2017. Dr. Naughton served as the Chairman and Chief Executive Officer of Histogen from June 2007 until April 2017. Prior to Histogen, Dr. Naughton was the Vice Chairman of Advanced Tissue Sciences, Inc., a human-based tissue engineering company, from March 2002 to October 2002, President from August 2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and Executive Vice President, Chief Operating Officer from 1991 to 1995. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. She has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S. and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal filler (Cosmederm/Cosmeplast), and SkinMedica's TNS product for skin care. Dr. Naughton has been extensively published and a frequent speaker in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton previously served as a member of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until January 2018 and CEL-SCI Corporation [NYSE American: CVM] from August 2022 until April 2024.<br> **Key Qualifications and Experience**<br> We believe Dr. Naughton's extensive executive experience, her in-depth knowledge of the healthcare industry and regenerative medicine technology, her experience developing FDA-approved products, and her service on other public company boards and committees, provide the requisite qualifications, skills, perspectives, and experience that make her well qualified to serve on our Board of Directors. Dr. Naughton received her B.S. in Biology from St. Francis College, her M.S. in Histology and her Ph.D. in Hematology from the New York University Medical Center and her E.M.B.A. from UCLA. |
|  **JUSTIN ROBERTS** <br> **Director Since: 2022**<br> **Age: 43** <br> **Committees:** <br> **Audit <br>Compensation** | **Biographical Information**<br> Mr. Roberts is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. He currently serves as a Non-Executive Director of Mereo BioPharma Group plc [NASDAQ: MREO]. Before Rubric he spent seven years at Point72 Asset Management. Mr. Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment banker in their M&A practice.<br> **Key Qualifications and Experience** <br> We believe Mr. Roberts' extensive executive experience, his finance background, and his service on other public company boards and committees, provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of Directors. Mr. Roberts graduated with honors from Johns Hopkins University. |

---

&nbsp;&nbsp;&nbsp;&nbsp; 9 <br>

------

[**Table of Contents**](#TOC001)

**Executive Officers**<br>

The following table sets forth certain information regarding our current executive officers:

---

| | | |
|:---|:---|:---|
|  **Name** | **Age** | **Position** |
|  Marlan D. Walker | 51 | Chief Executive Officer |
|  Joseph Ziegler | 51 | Principal Financial and Accounting Officer |

---

Listed below are biographical descriptions of our current executive officers.

*Marlan Walker has served as Chief Executive Officer of our company since December 2022. Previously he served as General Counsel of our company from March 2016. Mr. Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as our Corporate and Intellectual Property Counsel from June 2013 until he became our General Counsel. Mr. Walker's experience is focused in management of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD included long*-term *portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life*-cycle *management, and Hatch*-Waxman *matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009, he moved to Luce Forward Hamilton & Scripps. Mr. Walker accepted an in*-house *position as Intellectual Property Counsel for Medicis Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013, Mr. Walker accepted a position at Kilpatrick Townsend & Stockton, but chose to move in*-house *again in June 2013, when he accepted a position at our company. Mr. Walker graduated from Arizona State University Sandra Day O'Connor College of Law with his J.D. in 2004, and an LL.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master's Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University.*

*Joseph Ziegler has served as Principal Financial and Accounting Officer of our company since August 2023 and has served as founder and chief executive officer of JZ Advisory Group, a consulting company largely focused on providing fractional CFO and outsourced accounting services to middle*-market *and entrepreneurial businesses, since January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end*-to-end *property solutions, from November 2018 to February 2021. Prior to joining Encompass, he held multiple roles as a CFO in the healthcare industry, including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler served as a director of Progressive Care Inc. from December 2021 until December 2024. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University.*

&nbsp;&nbsp;&nbsp;&nbsp; 10<br>

------

[**Table of Contents**](#TOC001)

### CORPORATE GOVERNANCE
**Director Independence**<br>

Since October 9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC, or Nasdaq, under the symbol "TXMD." From April 23, 2013 to October 6, 2017, our common stock was listed on the NYSE American under the symbol "TXMD." Under the rules of Nasdaq, independent directors must comprise a majority of a listed company's board of directors.

Our Board of Directors has affirmatively determined, after considering all the relevant facts and circumstances, that each of Dr. Gail Naughton, and Messrs. Tommy G. Thompson, Cooper C. Collins and Justin Roberts is an independent director, as "independence" is defined under the applicable rules and regulations of the SEC and the listing standards of Nasdaq, and does not have a relationship with us (either directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their exercise of independent judgment in carrying out their responsibilities as directors. Accordingly, a majority of our directors are independent, as required under the applicable Nasdaq rules.

No director nominee or continuing director is related by blood, marriage, or adoption to any director, executive officer or person chosen to become a director or executive officer. No arrangements or understandings exist between any director nominee or continuing director and any other person pursuant to which such person was selected as a director or nominee. Further, there are no legal proceedings to which any director nominee or continuing director is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or any of our subsidiaries.

**Committee Charters, Corporate Governance, and Code of Ethics**<br>

Our Board of Directors has adopted charters for the Audit and Compensation Committees describing the authority and responsibilities delegated to each committee by our Board of Directors. Our Board of Directors has also adopted Corporate Governance Guidelines, a Code of Conduct and Ethics, and a Code of Ethics for the Chief Executive Officer and senior financial officers of our Company. We post on our website, at *www.therapeuticsmd.com*: the charters of our Audit and Compensation Committees; our Corporate Governance Guidelines, Code of Conduct and Ethics, and Code of Ethics for the Chief Executive Officer and senior financial officers, and any amendments or waivers thereto; and any other corporate governance materials contemplated by the SEC or Nasdaq. These documents are also available in print to any stockholder requesting a copy in writing from our corporate secretary at our executive offices set forth in this proxy statement.

**Executive Sessions**<br>

We regularly schedule executive sessions in which non-employee directors will meet without the presence or participation of management, with at least one of such sessions including only independent directors. Mr. Thompson, as the Chairman of our Board of Directors, chairs the executive sessions.

**Board Committees**<br>

Our Board of Directors has an Audit Committee and a Compensation Committee, each consisting entirely of independent directors.

Given the relatively small size of our Board of Directors and the desire to involve the entire Board of Directors in nominating decisions, we have elected to no longer have a separate Nominating Committee. Since we do not have a Nominating Committee, our independent directors, who currently constitute all of the Board of Directors, determine the director nominees. Our Board of Directors may employ a variety of methods for identifying and evaluating director nominees. If vacancies are anticipated or arise, our Board of Directors considers various potential candidates who may come to their attention through current Board members, professional search firms, stockholders or other persons. These candidates may be evaluated by our Board of Directors at any time during the year.

&nbsp;&nbsp;&nbsp;&nbsp; 11 <br>

------

[**Table of Contents**](#TOC001)

In evaluating a director candidate, our Board of Directors will review their qualifications including capability, availability to serve, conflicts of interest, general understanding of business, understanding of our business and technology, educational and professional background, personal accomplishments and other relevant factors. Our Board of Directors has not established any specific qualification standards for director nominees, and we do not have a formal diversity policy relating to the identification and evaluation of nominees for director, although from time to time the Board of Directors may identify certain skills or attributes as being particularly desirable to help meet specific needs that have arisen. Our Board of Directors may also interview prospective nominees in person or by telephone. After completing this evaluation, the Board of Directors will determine the nominees. The Board has not adopted a formal process for considering director candidates who may be recommended by stockholders. However, our policy is to give due consideration to any and all such candidates.

---

| | |
|:---|:---|
|  **Audit Committee** | **Audit Committee** |
|  **Members**<br> Cooper C. Collins, *Chair*<br> Justin Roberts <br>Tommy G. Thompson | The purpose of the Audit Committee is to oversee our financial and reporting processes and the audits of our financial statements and to provide assistance to our Board of Directors with respect to its oversight of the integrity of our financial statements, our Company's compliance with legal and regulatory matters, the independent registered public accountant's qualifications and independence, and the performance of our independent registered public accountant. The primary responsibilities of the Audit Committee are set forth in its charter and include various matters with respect to the oversight of our accounting and financial reporting process and audits of our financial statements on behalf of our Board of Directors. The Audit Committee also selects the independent registered public accountant to conduct the annual audit of our financial statements; reviews the proposed scope of such audit; reviews accounting and financial controls with the independent registered public accountant and our financial accounting staff; and reviews and approves any transactions between us and our directors, officers, and their affiliates.<br> The Audit Committee currently consists of Messrs. Collins, Thompson and Roberts, each an independent director of our Company under the listing standards of Nasdaq as well as under applicable rules and regulations of the SEC, with Mr. Collins serving as Chair. Our Board of Directors has determined that Mr. Thompson (whose background is detailed above) qualifies as an "audit committee financial expert" in accordance with applicable rules and regulations of the SEC. |
|  **Compensation Committee** | **Compensation Committee** |
|  **Members**<br> Gail Naughton, *Chair* <br>Cooper C. Collins <br>Justin Roberts | The purpose of the Compensation Committee includes, among other things, determining, or recommending to our Board of Directors for determination, the compensation of our Chief Executive Officer and other executive officers and directors, and discharging the responsibilities of our Board of Directors relating to our compensation programs. Pursuant to its charter, the Compensation Committee may delegate any of its responsibilities to a subcommittee comprised of one or more members of the Compensation Committee. The Compensation Committee currently consists of Dr. Naughton and Messrs. Collins and Roberts, each an independent director of our Company under the listing standards of Nasdaq as well as under applicable rules and regulations of the SEC, with Dr. Naughton serving as Chair. |

---

&nbsp;&nbsp;&nbsp;&nbsp; 12<br>

------

[**Table of Contents**](#TOC001)

**Board's Role in Risk Oversight**<br>

Risk is inherent in every business. As is the case in virtually all businesses, we face a number of risks, including operational, economic, financial, legal, regulatory, and competitive risks. Our management is responsible for the day-to-day management of the risks we face. Our Board of Directors, as a whole and through its committees, has responsibility for the oversight of risk management.

Our Board of Directors' involvement in our business strategy and strategic plans plays a key role in its oversight of risk management, its assessment of management's risk appetite, and its determination of the appropriate level of enterprise risk. Our Board of Directors receives updates at least quarterly from senior management and periodically from outside advisors regarding the various risks we face, including operational, cybersecurity and information technology, economic, financial, legal, regulatory, and competitive risks. Our Board of Directors also reviews the various risks we identify in our filings with the SEC as well as risks relating to various specific developments, such as debt and equity issuances.

The committees of our Board of Directors assist our Board of Directors in fulfilling its oversight role in certain areas of risks. The Audit Committee oversees the financial and reporting processes of our Company and the audit of the financial statements of our Company and provides assistance to our Board of Directors with respect to the oversight and integrity of the financial statements of our Company, our Company's compliance with legal and regulatory matters, the independent auditor's qualification and independence, and the performance of our independent auditor. The Audit Committee also receives reports regarding our compliance program and our cybersecurity and information technology programs. The Compensation Committee considers the risks that our compensation policies and practices may have in attracting, retaining, and motivating valued employees and endeavors to assure that it is not reasonably likely that our compensation plans and policies would create undue risk or have a material adverse effect on our Company.

**Board Composition**<br>

We seek a broad range of experiences, viewpoints, educational backgrounds, skills, and other individual qualities and attributes to be represented on our Board of Directors. We believe directors should have various qualifications, including individual character and integrity; business experience and leadership ability; strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters; communications and interpersonal skills; and the ability and willingness to devote time to our Company. We also believe the skill sets, backgrounds, and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional experience, background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis of race, religion, national origin, sex, sexual orientation, disability, or any other basis prohibited by law. The assessment of directors is made in the context of the perceived needs of our Board of Directors from time to time.

All of our directors have held high-level positions in business or professional service firms and have experience in dealing with complex issues. We believe that all of our directors are individuals of high character and integrity, are able to work well with others, and have committed to devote sufficient time to the business and affairs of our Company. In addition to these attributes, the description of each director's background set forth above indicates the specific experience, qualifications, and skills necessary to conclude that each individual should continue to serve as a director of our Company.

&nbsp;&nbsp;&nbsp;&nbsp; 13 <br>

------

[**Table of Contents**](#TOC001)

**Board Leadership Structure**<br>

We believe that effective board leadership structure depends on the experience, skills, and personal interaction among persons in leadership roles as well as the needs of our Company at any point in time. We currently maintain separate roles between the Chief Executive Officer and the Chairman of the Board of Directors in recognition of the differences between the two responsibilities. Our Chief Executive Officer is responsible for setting our strategic direction and day-to-day leadership and performance of our Company. The Chairman of the Board of Directors provides input to the Chief Executive Officer, sets the agenda for board meetings, and presides over meetings of the full Board of Directors as well as executive sessions of our Board of Directors. Our Board of Directors believes that our current leadership structure provides the most effective leadership model for our Company, as it promotes balance between the Board of Directors' independent authority to oversee our business and the Chief Executive Officer and his management team, which manage the business on a day-to-day basis.

**Compensation Committee Interlocks and Insider Participation**<br>

During our fiscal year ended December 31, 2024, Dr. Naughton and Messrs. Collins and Roberts served as members of the Compensation Committee.

None of Dr. Naughton and Messrs. Collins and Roberts have been at any time one of our officers or employees or had any relationship with us that requires disclosure under Item 404 of Regulation S-K under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

During the fiscal year ended December 31, 2024, none of our executive officers served on the compensation committee or board of directors of any entity whose executive officers serve as a member of our Board of Directors or Compensation Committee.

**Compensation Recovery Policy**<br>

In 2023, we adopted a policy on recoupment of incentive compensation, or clawback policy, which provides for recoupment of compensation in certain circumstances in the event of a restatement of our financial results, in accordance with the requirements of SEC rules and Nasdaq listing standards implementing the requirement of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act").

**Anti-Hedging and Anti-Pledging Policy**<br>

In April 2020, the Board of Directors amended the Company's Code of Conduct and Ethics to include a policy regarding hedging and pledging transactions. Pursuant to the policy, directors, officers, and employees are prohibited from: (1) directly or indirectly engaging in any hedging transactions with respect to any directly or indirectly owned securities of the Company, which includes the purchase of any financial instrument (including puts, calls, equity swaps, forward contracts, collars, exchange funds or other derivative securities) on an exchange or in any other market in order to hedge or offset any decrease in the market value of such securities; (2) engaging in short sale transactions or forward sale transactions or any short-term or speculative transactions in the Company's securities or in other transactions in the Company's securities that may lead to inadvertent violations of insider trading laws; and (3) pledging securities of the Company as collateral for a loan or otherwise using securities of the Company to secure a debt, including through the use of traditional margin accounts with a broker.

**Insider Trading Policy**<br>

On March 25, 2025, our Board of Directors adopted an insider trading policy that governs transactions in our securities by our directors, officers, employees and their respective family members and affiliates that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards. In addition, it is our policy to comply with federal securities laws and applicable stock exchange listing standards regarding trading in our own securities. A copy of our insider trading policy is included as Exhibit 19 to the Form 10-K filed on March 27, 2025.

&nbsp;&nbsp;&nbsp;&nbsp; 14<br>

------

[**Table of Contents**](#TOC001)

**Board and Committee Meetings**<br>

Our Board of Directors held a total of nine (9) meetings during the fiscal year ended December 31, 2024. No director attended fewer than 75% of the aggregate of (i) the total number of meetings of our Board of Directors and (ii) the total number of meetings held by all committees of our Board of Directors on which such director was a member.

During the fiscal year ended December 31, 2024, the Audit Committee held four (4) meetings and the Compensation Committee held zero (0) meetings.

**Annual Meeting Attendance**<br>

We encourage our directors to attend each annual meeting of stockholders. Two of our directors virtually attended the 2024 annual meeting of stockholders.

**Communications with Directors**<br>

Stockholders may communicate with our Board of Directors or specific members of our Board of Directors, including our independent directors and the members of our various board committees, by submitting a letter addressed to our Board of Directors of TherapeuticsMD, Inc. at the address set forth in this proxy statement c/o any specified individual director or directors. Any such letters are forwarded to the indicated directors. In addition, at the request of the Board of Directors, communications that do not directly relate to our Board of Directors' duties and responsibilities as directors will be excluded from distribution. Such excluded items include, among others, "spam," advertisements, mass mailings, form letters, and email campaigns that involve unduly large numbers of similar communications; solicitations for goods, services, employment or contributions; and surveys. Additionally, communications that appear to be unduly hostile, intimidating, threatening, illegal or similarly inappropriate will also be screened for omission. Any excluded communication will be made available to any director upon his or her request.

&nbsp;&nbsp;&nbsp;&nbsp; 15 <br>

------

[**Table of Contents**](#TOC001)

### EXECUTIVE COMPENSATION
Our Board of Directors has appointed a Compensation Committee, consisting of independent members of our Board of Directors, to review and approve corporate goals and objectives relevant to the compensation of our Chief Executive Officer, or CEO, evaluate the performance of our CEO on achieving those goals and objectives, and determine or recommend to our Board of Directors the compensation of our CEO based on this evaluation. The Compensation Committee also recommends to our Board of Directors, or as directed by our Board of Directors, determines and approves, the compensation of our other executive officers. The Compensation Committee makes every effort to ensure our executive compensation program is consistent with our values and is aligned with our business strategy and corporate goals.

As a smaller reporting company, the rules of the U.S. Securities and Exchange Commission permit us to omit the Compensation Discussion and Analysis section and to report the compensation of our principal executive officer, each of our two other most highly compensated executive officers who were serving at the end of our last completed fiscal year, and up to two additional former executive officers for whom disclosure would have been provided but for the fact that the individual was not serving as an executive officer at the end of our last completed fiscal year (collectively, our "NEOs").

For 2024, our NEOs were:

• Marlan Walker, CEO

• Joseph Ziegler, Principal Financial and Accounting Officer

As of December 31, 2024, we employed one full-time employee primarily engaged in an executive position — Mr. Marlan Walker, our Chief Executive Officer. Mr. Ziegler serves as our Principal Financial and Accounting Officer pursuant to a master services agreement (the "Master Services Agreement") with JZ Advisory Group ("JZ Advisory"). See "Ziegler Master Services Agreement" below.

&nbsp;&nbsp;&nbsp;&nbsp; 16<br>

------

[**Table of Contents**](#TOC001)

**Fiscal Year 2024 Summary Compensation Table**<br>

The following table lists the compensation of our NEOs for the years provided. The following information includes the dollar value of salaries, bonus awards, the number of awards granted, non-equity incentive plan compensation, and certain other compensation, if any.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  **Name and Principal Position** | **Year** | **Salary<br>($)** | **Bonus<br>($)** | **Stock<br>Awards<sup>(1)</sup><br>($)** | **Option<br>Awards<br>($)** | **Non-Equity<br>Incentive Plan<br>Compensation<sup>(2)</sup><br>($)** | **All Other<br>Compensation<br>($)** | **Total<br>($)** |
|  **Marlan D. Walker** | 2024 | 500000 |  |  |  | 250000 | 9174<br><sup>(6)</sup> | 759174 |
|  Chief Executive Officer | 2023 | 476462 | 176535<br><sup>(4)</sup> | 358400<br><sup>(5)</sup> |  |  | 8420<br><sup>(6)</sup> | 1019817 |
|  **Joseph Ziegler**<sup>(3)</sup> | 2024 | 120000<br><sup>(7)</sup> |  |  |  |  |  | 120000 |
|  Principal Financial and Accounting Officer | 2023 | 52900<br><sup>(7)</sup> |  | 30000<br><sup>(8)</sup> |  |  |  | 82900 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp; Represents the grant date fair value of restricted stock units (RSUs) and performance restricted stock units (PSUs) granted. The number of PSUs represents the maximum number of PSUs that may vest. The actual number of PSUs that will vest will depend on the Company's achievement of certain performance goals.

(2)&nbsp;&nbsp;&nbsp;&nbsp; Amounts in this column represent the amounts earned and payable under our annual performance-targeted incentive plan, which were earned and payable during the indicated fiscal year but portions of which may not have been paid until after the end of indicated fiscal year.

(3)&nbsp;&nbsp;&nbsp;&nbsp; On August 17, 2023, Mr. Ziegler began serving as Principal Financial and Accounting Officer of the Company.

(4)&nbsp;&nbsp;&nbsp;&nbsp; Amount represents retention bonus[es].

(5)&nbsp;&nbsp;&nbsp;&nbsp; For 2023, the amount represents 70,000 RSUs with a grant date fair value of $358,400.

(6)&nbsp;&nbsp;&nbsp;&nbsp; Other compensation paid was related to (i) employer match to 401(k) plan of $2,000 (for fiscal year 2023), and (ii) health and welfare benefits paid by the Company (for both fiscal year 2023 and fiscal year 2024).

(7)&nbsp;&nbsp;&nbsp;&nbsp; The amounts represent the fixed fee paid to JZ Advisory in accordance with the Master Services Agreement.

(8)&nbsp;&nbsp;&nbsp;&nbsp; For 2023, the amount represents 7,500 RSUs with a grant date fair value of $30,000.

&nbsp;&nbsp;&nbsp;&nbsp; 17 <br>

------

[**Table of Contents**](#TOC001)

**Outstanding Equity Awards at Fiscal Year-End 2024**<br>

The following tables set forth information with respect to outstanding equity-based awards held by our NEOs at December 31, 2024.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Name** | **Equity <br>Award <br>Date** | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** |
|  **Name** | **Equity <br>Award <br>Date** | **Number of Securities<br>Underlying Unexercised Options** | **Number of Securities<br>Underlying Unexercised Options** | **Option<br>Exercise Price<br>($)** | **Option<br>Expiration<br>Date** |
|  **Name** | **Equity <br>Award <br>Date** | **Exercisable<br>(#)** | **Unexercisable<br>(#)** | **Option<br>Exercise Price<br>($)** | **Option<br>Expiration<br>Date** |
|  **Marlan D. Walker** | 07/30/2019 | 4000 |  | 109.00 | 07/30/2029 |
|  **Joseph Ziegler** |  |  |  |  |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Name** | **Equity <br>Award <br>Date** | **Stock Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** |
|  **Name** | **Equity <br>Award <br>Date** | |  | **Equity Incentive Plan Awards** | **Equity Incentive Plan Awards** |
|  **Name** | **Equity <br>Award <br>Date** | **Number of <br>Shares or <br>Units of <br>Stock <br>That Have <br>Not Vested <br>(#)** | **Market <br>Value of <br>Shares or <br>Units of <br>Stock <br>That Have <br>Not Vested<sup>(1)</sup><br>($)** | **Number of <br>Shares or <br>Units of <br>Stock <br>That Have <br>Not Vested <br>(#)** | **Market <br>Value of <br>Shares or <br>Units of <br>Stock <br>That Have <br>Not Vested<sup>(1)</sup><br>($)** |
|  **Marlan D. Walker** | 03/23/2022 | 1733<br><sup>(2)</sup> | 1490 |  |  |
|  | 03/31/2022 | 5200<br><sup>(3)</sup> | 4472 |  |  |
|  **Joseph Ziegler** |  |  |  |  |  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp; The amounts in this column are based on the closing price of our common stock on December 31, 2024 of $0.86.

(2)&nbsp;&nbsp;&nbsp;&nbsp; The amount reflects 1,733 RSUs that vested on March 23, 2025.

(3)&nbsp;&nbsp;&nbsp;&nbsp; The amount reflects 5,200 PSUs that vested on April 5, 2025.

&nbsp;&nbsp;&nbsp;&nbsp; 18<br>

------

[**Table of Contents**](#TOC001)

**Post-Employment Compensation**<br>

#### Pension Benefits
We do not offer any defined benefit pension plans for any of our employees.

#### Other Compensation
Mr. Walker is eligible to participate in our employee benefit plans, including medical and dental plans. Should we decide to hire other employees, these plans do not discriminate in favor of executive officers and would be available to any potential employee. It is generally our policy to not extend significant perquisites to executives that are not broadly available to our other employees. In designing these elements, we seek to provide an overall level of benefits that is competitive with that offered by similarly situated companies in the markets in which we operate based upon our general understanding of industry practice. These benefits are not considered in determining the compensation of our executive officers.

**Employment Agreement**<br>

Marlan D. Walker has an amended and restated employment agreement, as amended (the "Walker Employment Agreement"), with the Company that commenced on December 18, 2018, and was amended effective October 15, 2021, December 30, 2022, February 21, 2023 and December 17, 2024. The Walker Employment Agreement provides that we will continue to employ Mr. Walker, and Mr. Walker will continue to serve the Company, unless sooner terminated pursuant to the terms of the Walker Employment Agreement. The Walker Employment Agreement provides for: (i) a base salary of $428,000 per year until April 15, 2023; thereafter, a base salary of $500,000 per year and a lump-sum bonus payment of $20,909, which was paid in April 2023 (ii) an annual short-term incentive compensation of 50% of salary, at the discretion of our Board of Directors, and (iii) 70,000 RSUs vesting on June 30, 2023. Mr. Walker will receive employee benefits, vacation, and other perquisites as may be determined from time to time.

Conditions of termination call for (i) termination immediately upon death, (ii) termination upon a disability in which Mr. Walker is unable to perform his duties for more than six (6) consecutive months, (iii) voluntary termination without good reason by Mr. Walker with prior notice, (iv) involuntary termination by our Company without good cause, (v) termination for good cause, and (vi) termination for good reason wherein Mr. Walker will have ninety (90) days from the date of occurrence of a condition giving rise to good reason to provide a notice of termination of his employment with the Company, which will be effective thirty-one (31) days after we receive notice and the criteria remains uncorrected.

**Master Services Agreement**<br>

We entered into the Master Services Agreement with JZ Advisory that commenced on August 15, 2023, pursuant to which, among other things, JZ Advisory will serve as an independent consultant for the purpose of providing the Company with certain support services, including the services of Mr. Ziegler as the Company's Principal Financial Officer.

The Company agreed to pay JZ Advisory $10,000 a month for the services provided under the Master Services Agreement during the third quarter of 2023, which monthly rate will continue until the parties negotiate a future retainer amount. Mr. Ziegler was also granted 7,500 restricted stock units, which vested on August 17, 2024. The Master Services Agreement will continue through the third anniversary of the Effective Date, unless earlier terminated (the "Term"). The Term will automatically be extended for successive one-year periods unless either party provides written notice of non-extension no less than thirty (30) days in advance. The Master Services Agreement may be terminated pursuant to its terms. The Master Services Agreement contains certain covenants and agreements of the parties, including certain indemnification obligations of each party.

&nbsp;&nbsp;&nbsp;&nbsp; 19 <br>

------

[**Table of Contents**](#TOC001)

**Potential Payments Upon Termination or Change in Control**<br>

We have employment agreements with certain of our executive officers as described above. The arrangements reflected in these employment agreements are designed to encourage the officers' full attention and dedication to our Company currently and, in the event of any proposed change in control, provide these officers with individual financial security. The employment agreements provide for specified payments and benefits by us to our executive officers only upon a qualifying termination of employment as described below.

#### Termination by Us Without Good Cause or by Executive with Good Reason — No Change in Control
Under the Walker Employment Agreement, for Mr. Walker, in the event of termination of the executive's employment without "cause" (referred to as "good cause" in the Walker Employment Agreement) or resignation by the executive for "good reason" (as each term is defined in the Walker Employment Agreement), he would be entitled to, subject to his signing and not revoking a full and complete release of all claims against the Company and its affiliates, (i) the sum of his salary, payable on a biweekly basis ratably over eighteen (18) months, and one and one half times (1.5x) his target annual incentive compensation for the fiscal year in which such termination of employment occurs, (ii) a continuation of welfare benefits for a period of two years after such termination, (iii) COBRA benefits for a period of twenty-four (24) months following such termination, (iv) payment for any annual short-term incentive compensation earned for the calendar year immediately preceding the calendar year of such termination, (v) unpaid accrued base salary and unused vacation pay through the termination date, and (vi) amounts accrued but unpaid at the time of termination. Furthermore, the above obligations of the Company are subject to the executive complying with a non-solicitation agreement of employees and customers, and a non-competition agreement.

#### Termination or Resignation in Connection with a Change in Control
In the event of termination of Mr. Walker's employment without "good cause" or resignation by the executive for "good reason" in the twelve (12) months following a change in control, Mr. Walker would be entitled to, subject to his signing and not revoking a full and complete release of all claims against the Company and its affiliates, (i) the sum of his salary, payable on a biweekly basis ratably over eighteen (18) months, and one and one half times (1.5x) his target annual incentive compensation for the fiscal year in which such termination of employment occurs, (ii) payment for any annual short-term incentive compensation earned for the calendar year immediately preceding the calendar year of such termination, (iii) unpaid accrued base salary and unused vacation pay through the termination date, and (iv) amounts accrued but unpaid at the time of termination. Furthermore, the above obligations of the Company are subject to the executive complying with a non-solicitation agreement of employees and customers, and a non-competition agreement.

#### Termination by Reason of Death or Disability
For Mr. Walker, in the event of termination of the executive's employment by reason of his death or "disability" (as such term is defined in the Walker Employment Agreement), in addition to those payments and benefits provided to salaried employees generally, including amounts accrued but unpaid at the time of termination, he would be entitled to (i) pro-rated target annual incentive compensation for the fiscal year in which such termination of employment occurs, payable in a lump sum, subject to the executive's signing and not revoking a full and complete release of all claims against the Company and its affiliates in the event of a disability, (ii) immediate vesting of all outstanding equity awards that vest solely on the passage of time, (iii) accrued but unused vacation pay through the termination date, payable in a lump sum, and (iv) all other rights and benefits the executive is vested in, pursuant to other plans and programs of our Company.

&nbsp;&nbsp;&nbsp;&nbsp; 20<br>

------

[**Table of Contents**](#TOC001)

#### Termination by the Executive Without Good Reason
The table below reflects the amount of compensation to Marlan Walker, the only NEO currently employed by the Company, assuming termination of such executive's employment without cause or for good reason or following a change in control of our Company on December 31, 2024. Other than as set forth below, no amounts will be paid to our NEOs in the event of termination.

<u>**Marlan Walker**</u>

---

| | | | |
|:---|:---|:---|:---|
|  **Executive Benefits and Payments** | **Termination<br>Without Good<br>Cause<br>or with Good<br>Reason (Not in<br>Connection with<br>a Change<br>in Control)<br>($)** | **Termination<br>Without Good<br>Cause<br>or with Good<br>Reason<br>Following<br>a Change<br>in Control<br>($)** | **Termination by<br>Reason of<br>Death or<br>Disability<br>($)** |
|  Cash severance | 1178362<br><sup>(1)</sup> | 1176575<br><sup>(2)</sup> | 250000<br><sup>(3)</sup> |
|  Equity awards<sup>(4)</sup> | 5962 | 5962 | 5962 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp; Consists of payments due to executive for (i) eighteen (18) months of his then current salary, (ii) 150% target annual incentive compensation, (iii) health and welfare benefits for twenty-four (24) months, (iv) unused PTO, and (v) any annual short-term incentive compensation earned from the prior year that had not yet been paid by the Company.

(2)&nbsp;&nbsp;&nbsp;&nbsp; Consists of payments due to executive for (i) eighteen (18) months of his then current salary, (ii) 150% target annual incentive compensation, (iii) unused PTO, and (iv) any annual short-term incentive compensation earned from the prior year that had not yet been paid by the Company.

(3)&nbsp;&nbsp;&nbsp;&nbsp; Represents full annual incentive compensation that would be prorated based on termination date.

(4)&nbsp;&nbsp;&nbsp;&nbsp; Represents the value of unvested equity awards that would become fully vested. The value is calculated by multiplying the number of shares underlying each accelerated award by the per share closing price of the common stock on December 29, 2024.

**Nonqualified Defined Contribution and Nonqualified Deferred Compensation**<br>

We do not offer any nonqualified defined contribution plans or nonqualified deferred compensation plans for any of our NEOs.

**Limitation of Directors' Liability; Indemnification of Directors, Officers, Employees, and Agents**<br>

Our Amended and Restated Articles of Incorporation and bylaws, each as amended, provide that we may indemnify to the full extent of our power to do so, all directors, officers, employees, and/or agents. The effect of this provision in the Amended and Restated Articles of Incorporation, as amended, is to eliminate the rights of our Company and our stockholders, either directly or through stockholders' derivative suits brought on behalf of our Company, to recover monetary damages from a director for breach of the fiduciary duty of care as a director except in those instances described under Nevada law.

Insofar as indemnification by our Company for liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), may be permitted to officers and directors of our Company pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

&nbsp;&nbsp;&nbsp;&nbsp; 21 <br>

------

[**Table of Contents**](#TOC001)

**Pay vs. Performance Comparison**<br>

As required by Item 402(v) of Regulation S-K, the information below reflects the relationship between executive compensation actually paid by us to our PEOs, as principal executive officer, and other non-CEO NEOs ("Other NEOs") and our financial performance for the years ended December 31, 2022, 2023 and 2024. The disclosure included in this section is required by SEC rules and does not necessarily align with how the Company or the Compensation Committee views the link between the Company's performance and the compensation of its NEOs.

The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years presented.

The following table sets forth information regarding actual compensation paid to our PEOs and Other NEOs for service during each of the last three completed fiscal years, as applicable.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  **(a)** | **(b)** | **(c)** | **(d)** | **(e)** | **(f)** | **(g)** | **(h)** | **(i)**  |
|  **Year<sup>(1)</sup>** | **Summary <br>Compensation <br>Table Total <br>for Hugh <br>O'Dowd<sup>(2)</sup>** | **Compensation <br>Actually paid <br>to Hugh <br>O'Dowd<sup>(3)</sup>** | **Summary <br>Compensation <br>Table Total <br>for Brian <br>Bernick<sup>(2)</sup>** | **Compensation <br>Actually paid <br>to Brian <br>Bernick<sup>(3)</sup>** | **Summary <br>Compensation <br>Table Total <br>for Mark <br>Glickman<sup>(2)</sup>** | **Compensation <br>Actually <br>paid to Mark <br>Glickman<sup>(3)</sup>** | **Summary <br>Compensation <br>Table Total <br>for Marlan <br>Walker<sup>(2)</sup>** | **Compensation <br>Actually paid <br>to Marlan <br>Walker<sup>(3)</sup>** |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A | $759174 | $759174 |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A | $1019817 | $888913 |
| 2022<sup>(7)</sup> | $3664308 | $419883 | $1624016 | $1143643 | $1428728 | $975497 | $1573380 | $1167185 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **(j)** | **(k)** | **(l)** | **(m)** | **(n)** |
|  **<br>Year** | **Average <br>Summary <br>Compensation <br>Table Total <br>for Non-PEO <br>Named <br>Executive <br>Officers<sup>(4)</sup>** | **Average <br>Compensation <br>Actually Paid <br>to Non-PEO <br>Named <br>Executive <br>Officers<sup>(5)</sup>** | **Value of <br>Initial Fixed <br>$100 <br>Investment <br>Based on <br>Total <br>Shareholder <br>Return<sup>(6)</sup>** | **Net Income <br>(in thousands)** |
| 2024<sup>(1)</sup> | $120000 | $102525 | $1.70 | $(2181) |
| 2023<sup>(1)</sup> | $684782 | $678220 | $3.72 | $(10278) |
| 2022<sup>(1)</sup> | $561065 | $426954 | $9.24 | $111997 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp; During 2023 and 2024, our Chief Executive Officer was Marlan Walker. During 2022, our Chief Executive Officers were Hugh O'Dowd, Brian Bernick, Mark Glickman and Marlan Walker. During 2024, our remaining NEO consisted of Joseph Ziegler. During 2023, our remaining NEOs consisted of Joseph Ziegler and Michael Donegan. During 2022, our remaining NEOs consisted of Michael Donegan and James C. D'Arecca.

(2)&nbsp;&nbsp;&nbsp;&nbsp; The dollar amounts reported in columns (b), (d), (f) and (h) represent the amount of total compensation reported for Mr. O'Dowd, Dr. Bernick, Mr. Glickman and Mr. Walker (collectively, our "PEOs") for each covered fiscal year in the "Total" column of the Summary Compensation Table for each applicable year.

&nbsp;&nbsp;&nbsp;&nbsp; 22<br>

------

[**Table of Contents**](#TOC001)

(3)&nbsp;&nbsp;&nbsp;&nbsp; The dollar amounts reported in columns (c), (e), (g) and (i) represent the amount of "compensation actually paid" to our PEOs, as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid to the PEOs during the applicable fiscal year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the total compensation for 2024 to determine the "compensation actually paid" to our PEOs for such fiscal year:

---

| | |
|:---|:---|
|  **Adjustments to Determine Compensation "Actually Paid" for CEO** | **Marlan <br>Walker<br>2024** |
|  Summary Compensation Table – Total Compensation | $759174 |
|  Deduction for Amounts Reported under the "Stock Awards" Column in the Summary Compensation Table |  |
|  Deduction for Amounts Reported under the "Option Awards" Column in the Summary Compensation Table |  |
|  Increase for fair value of awards granted during the year that remain unvested as of year-end |  |
|  Increase for fair value of awards granted during the year that vested during the year |  |
|  Increase/deduction for change in fair value from prior year-end to current year-end of awards granted in prior year that were outstanding and unvested as of year-end |  |
|  Increase/deduction for change in fair value from prior year-end to vesting date of awards granted in prior year that vested during the year |  |
|  Decrease for change in fair value from prior year-end to vesting date of awards granted in prior year that were forfeited during the year |  |
|  Increase based upon incremental fair value of awards modified during year |  |
|  Increase based on dividends or other earnings paid during year prior to vesting date of award |  |
|  Total Adjustments to Summary Compensation |  |
|  Total Compensation Actually Paid | 759174 |

---

(4)&nbsp;&nbsp;&nbsp;&nbsp; The dollar amounts reported in column (k) represent the average amount of total compensation reported for our NEOs as a group (excluding our PEOs) for each covered fiscal year in the "Total" column of the Summary Compensation Table for each applicable year.

(5)&nbsp;&nbsp;&nbsp;&nbsp; The dollar amounts reported in column (l) represent the average amount of "compensation actually paid" to our NEOs as a group (excluding our PEOs), as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual average amount of compensation earned or received by or paid to our NEOs as a group (excluding our PEOs) during the applicable fiscal year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the average total compensation for 2024 to determine the "compensation actually paid" to our NEOs as a group (excluding our PEOs) for such fiscal year:

---

| | |
|:---|:---|
|  **Adjustments to Determine Compensation "Actually Paid" for Other NEOs** | **2024** |
|  Summary Compensation Table – Total Compensation | 120000 |
|  Deduction for Amounts Reported under the "Stock Awards" Column in the Summary Compensation Table |  |
|  Deduction for Amounts Reported under the "Option Awards" Column in the Summary Compensation Table |  |
|  Increase for fair value of awards granted during the year that remain unvested as of year-end |  |
|  Increase for fair value of awards granted during the year that vested during the year |  |
|  Increase/deduction for change in fair value from prior year-end to current year-end of awards granted in prior year that were outstanding and unvested as of year-end |  |
|  Increase/deduction for change in fair value from prior year-end to vesting date of awards granted in prior year that vested during the year | (17475) |
|  Decrease for change in fair value from prior year-end to vesting date of awards granted in prior year that were forfeited during the year |  |
|  Increase based upon incremental fair value of awards modified during year |  |
|  Increase based on dividends or other earnings paid during year prior to vesting date of award |  |
|  Total Adjustments to Summary Compensation | (17475) |
|  Total Compensation Actually Paid | $102525 |

---

(6)&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to rules of the SEC, the comparison assumes $100 was invested on December 31, 2021 in our common stock. Historic stock price performance is not necessarily indicative of future stock price performance.

(7)&nbsp;&nbsp;&nbsp;&nbsp; With respect to 2022, the Summary Compensation Table total as well as the Compensation Actually Paid for Mr. Walker and for Mr. Donegan, as reflected in the Compensation Actually Paid for the Other NEOs, have been updated to reflect the inadvertent exclusion of bonuses (Mr. Walker, $155,625 and Mr. Donegan, $67,500) paid in January 2023 that related to 2022 performance.

&nbsp;&nbsp;&nbsp;&nbsp; 23 <br>

------

[**Table of Contents**](#TOC001)

#### Analysis of Information Presented in the Pay Versus Performance Table
In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above.

#### Compensation Actually Paid and Net Income
&nbsp;&nbsp;&nbsp;&nbsp; 24<br>

------

[**Table of Contents**](#TOC001)

#### Compensation Actually Paid and Company TSR
All information provided above under the "Pay vs. Performance Comparison" heading will not be deemed to be incorporated by reference into any of TherapeuticsMD's filings under the Securities Act or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent TherapeuticsMD specifically incorporates such information by reference.

&nbsp;&nbsp;&nbsp;&nbsp; 25 <br>

------

[**Table of Contents**](#TOC001)

### EQUITY COMPENSATION PLAN INFORMATION
As of December 31, 2024, the following table shows the number of securities to be issued upon exercise of outstanding options under equity compensation plans approved by our stockholders, which plans do not provide for the issuance of warrants or other rights.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  **Plan Name** | **<br>(a) <br>Number of Securities to be Issued Upon** | **<br>(a) <br>Number of Securities to be Issued Upon** | **<br>(a) <br>Number of Securities to be Issued Upon** |  | **(c)<br>Number of <br>Securities <br>Remaining <br>Available For <br>Future <br>Issuance <br>Under Equity <br>Compensation <br>Plans <br>(Excluding <br>Securities <br>Reflected in <br>Columns (a))**<sup>(2)</sup> **<br>(#)** |
|  **Plan Name** | **Exercise of <br>Outstanding <br>Options <br>(#)** | **Vesting and <br>Settlement of <br>Restricted <br>Stock Units <br>("RSUs") <br>(#)** | **Vesting and <br>Settlement of <br>Performance <br>Stock Units <br>("PSUs")<sup>(1)</sup> <br>(#)** | **(b) <br>Weighted-<br>Average <br>Exercise <br>Price of <br>Outstanding <br>Options <br>($)** | **(c)<br>Number of <br>Securities <br>Remaining <br>Available For <br>Future <br>Issuance <br>Under Equity <br>Compensation <br>Plans <br>(Excluding <br>Securities <br>Reflected in <br>Columns (a))**<sup>(2)</sup> **<br>(#)** |
|  Equity Compensation Plans Approved by Stockholders |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; 2019 Plan | 19820 | 1733 | 5200 | 120.71 | 411000 |
| &nbsp;&nbsp;&nbsp;&nbsp; 2012 Plan | 7300 |  |  | 309.77 |  |
| &nbsp;&nbsp;&nbsp;&nbsp; 2009 Plan | 29410 |  |  | 310.43 |  |
|  Equity Compensation Plans Not Approved by Stockholders |  |  |  |  |  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp; The actual number of PSUs that will vest will be between zero and 5,200 depending on the Company's achievement of certain performance goals.

(2)&nbsp;&nbsp;&nbsp;&nbsp; The number of remaining shares of common stock available for future issuance is based on an assumption that the maximum performance goals for PSUs were achieved, where applicable.

&nbsp;&nbsp;&nbsp;&nbsp; 26<br>

------

[**Table of Contents**](#TOC001)

### CERTAIN TRANSACTIONS AND RELATIONSHIPS

#### Policy Relating to Related Party Transactions
We have a policy that we will not enter into any material transaction in which a director or officer has a direct or indirect financial interest unless the transaction is determined by our Board of Directors to be fair to us or is approved by a majority of our disinterested directors or by our stockholders, as provided for under Nevada law. Generally, our Board of Directors as a whole, other than an affected director, if applicable, determines whether a director or officer has a direct or indirect (*i.e.*, any) financial interest in a transaction deemed material based upon our Code of Conduct and Ethics and Nevada law. From time to time, our Audit Committee, in accordance with its charter, will also review potential conflict of interest transactions involving members of our Board of Directors and our executive officers. The policy with respect to such transactions is provided in our Company's Code of Conduct and Ethics.

#### Related Party Transactions
Other than compensation arrangements, we describe below transactions and series of similar transactions, since January 1, 2023, to which we were a party or will be a party, in which:

• the amounts involved exceeded or will exceed $120,000; and

• any of our directors, executive officers, or holders of more than 5% of our voting securities, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.

Compensation arrangements for our directors and NEOs are described elsewhere in this proxy statement.

#### Agreements with Rubric Capital Management LP
On August 23, 2022, we appointed Mr. Justin Roberts as a director to fill a newly created vacancy on the Board of Directors. As a director of the Company, Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, but he has elected not to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as a Partner of Rubric. On July 29, 2022, September 30, 2022, October 28, 2022 and May 1, 2023, we entered into subscription agreements with Rubric. On December 30, 2022, and in accordance with the terms of the Certificate of Designation, the Company redeemed all 29,000 outstanding shares of the Company's Series A Preferred Stock from Rubric at a purchase price of $1,333 per share. The Company also paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between the Company and Rubric. On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797 pursuant to the subscription agreement and received gross proceeds of $1.15 million before expenses. On November 15, 2023, Rubric drew down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from the drawdown before expenses.

&nbsp;&nbsp;&nbsp;&nbsp; 27 <br>

------

[**Table of Contents**](#TOC001)

### DIRECTOR COMPENSATION
We compensate our non-employee directors with a combination of cash and equity. Our Board of Directors receives the following cash compensation for their service: each director receives an annual cash retainer of $57,500; the chairperson of the Board receives an additional $22,500 annual cash retainer; the chairperson of our Audit Committee receives an annual cash retainer of $30,000 and the other members of the Audit Committee receive an annual cash retainer of $15,000; the chairperson of the Compensation Committee receives an annual cash retainer of $20,000 and the other members of the Compensation Committee receive an annual cash retainer of $12,000; and the chairperson of each of our other committees receives an annual cash retainer of $12,500 and the other members receive an annual cash retainer of $7,500. We also reimburse our directors for reasonable expenses related to attendance at Board of Directors and committee meetings. No directors were granted equity awards during 2024. We do not pay our directors per meeting fees.

The following table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2024. Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, but he has elected not to receive any compensation for his service as a non-employee director at this time, as discussed in Certain Transactions and Relationships above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **Name<sup>(1)</sup>** | **Fees Earned <br>or Paid in <br>Cash <br>($)** | **Stock <br>Awards<sup>(2)</sup><br>($)** | **All Other <br>Compensation <br>($)** | **Total <br>($)** |
|  **Tommy G. Thompson** | 101758<br><sup>(3)</sup> |  |  | 101758 |
|  **Cooper C. Collins** | 99500  |  |  | 99500 |
|  **Gail Naughton, Ph.D.** | 77500  |  |  | 77500 |
|  **Justin Roberts** | —  |  |  |  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp; As of December 31, 2024, each of the directors listed in the "Director Compensation" table had the following awards outstanding:

---

| | | |
|:---|:---|:---|
|  **Name** | **Option <br>Awards <br>(#)** | **Stock <br>Awards <br>(#)** |
|  **Tommy G. Thompson** | 7,250 | 8,500 |
|  **Cooper C. Collins** | 5,000 | 8,500 |
|  **Gail Naughton, Ph.D.** |  | 8,500 |
|  **Justin Roberts** |  |  |

---

The stock awards listed above include 8,500 restricted stock units that were vested but not settled as of December 31, 2024, for each of Mr. Thompson, Mr. Collins and Dr. Naughton, respectively.

(2)&nbsp;&nbsp;&nbsp;&nbsp; We grant RSUs for shares of common stock to non-employee directors. We value our RSUs by reference to our stock price on the date of grant. We recognize compensation expense for RSUs based on a straight-line basis over the requisite service period of the entire award.

(3)&nbsp;&nbsp;&nbsp;&nbsp; Reflects proration of Executive Chairman retainer for the portion of 2024 that Mr. Thompson served as Executive Chairman.

&nbsp;&nbsp;&nbsp;&nbsp; 28<br>

------

[**Table of Contents**](#TOC001)

### REPORT OF THE AUDIT COMMITTEE
The Board of Directors has appointed an Audit Committee consisting of independent directors. All of the members of the committee must be "independent" of our Company and management, as independence is defined in applicable rules of the SEC and the Nasdaq listing standards.

The purpose of the Audit Committee is to assist the oversight of our Board of Directors in the integrity of the financial statements of our Company, our Company's compliance with legal and regulatory matters, the independent auditor's qualifications and independence, and the performance of our Company's independent auditor and any internal audit function. The primary responsibilities of the committee include overseeing our Company's accounting and financial reporting process and audits of the financial statements of our Company.

Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls. The independent auditor is responsible for auditing the financial statements and expressing an opinion on the conformity of those audited financial statements with generally accepted accounting principles.

In this context, the Audit Committee met and held discussions with management and the independent registered public accounting firm. Management represented to the Audit Committee the audited financial statements were prepared in accordance with generally accepted accounting principles. The Audit Committee reviewed and discussed the audited financial statements with management and the independent registered public accounting firm. The Audit Committee discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board ("PCAOB") and the SEC. The independent registered public accounting firm also provided to the Audit Committee the written disclosures and the letter required by the applicable requirements of the PCAOB regarding the independent accountant's communications with the Audit Committee concerning independence. The Audit Committee discussed with the independent registered public accounting firm that firm's independence.

The Audit Committee discussed with our independent auditor the overall scope and plans for its audit. The Audit Committee meets with the independent auditor, with and without management present, to discuss the results of the independent auditor's examinations, its evaluations of our Company, the internal controls, and the overall quality of the financial reporting. The Audit Committee held five (5) meetings in 2024.

Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors, and the Board of Directors approved, that the audited financial statements be included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for filing with the SEC.

The report has been furnished by the Audit Committee of our Board of Directors.

<u> November 3, 2025 </u>   <u> Cooper C. Collins, Chair Justin RobertsTommy G. Thompson </u>

&nbsp;&nbsp;&nbsp;&nbsp; 29 <br>

------

[**Table of Contents**](#TOC001)

### DELINQUENT SECTION 16(A) REPORTS
Section 16(a) of the Exchange Act requires our directors, officers, and persons who own more than 10% of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. These regulations require the directors, officers, and persons who own more than 10% of a registered class of our equity securities to furnish us with copies of all Section 16(a) forms they file.

Based solely upon our review of the copies of such forms received by us during the fiscal year ended December 31, 2024, and written representations that no other reports were required, we believe that each person who, at any time during such fiscal year was a director, officer, or persons who own more than 10% of a registered class of our equity securities, complied with all Section 16(a) filing requirements during such fiscal year.

&nbsp;&nbsp;&nbsp;&nbsp; 30<br>

------

[**Table of Contents**](#TOC001)

### SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS, AND OFFICERS
The following table sets forth information regarding the beneficial ownership of our common stock as of October 20, 2025, by the following:

• each of our directors and named executive officers;

• all of our directors and executive officers as a group; and

• each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock.

Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power of that security, including options and warrants that are currently exercisable or exercisable within 60 days of October 20, 2025. Shares issuable pursuant to stock options, warrants, and convertible securities are deemed outstanding for computing the percentage of the person holding such options, warrants, or convertible securities but are not deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose.

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o TherapeuticsMD, Inc.,

951 Yamato Road, Suite 220, Boca Raton, Florida 33431.

---

| | | |
|:---|:---|:---|
|  | **Shares Beneficially Owned** | **Shares Beneficially Owned** |
|  **Name of Beneficial Owners** | **Number** | **Percent<sup>(1)</sup>** |
|  **Executive Officers and Directors:** |  |  |
|  Marlan D. Walker<sup>(2)</sup> | 84572 | \* |
|  Tommy G. Thompson<sup>(3)</sup> | 36362 | \* |
|  Cooper C. Collins<sup>(4)</sup> | 65516 | \* |
|  Gail K. Naughton, Ph.D.<sup>(5)</sup> | 8500 | \* |
|  Justin Roberts |  |  |
|  Joseph Ziegler<sup>(6)</sup> | 7500 | \* |
|  All executives and directors as a group (6 persons) | 202450 | 1.7% |
|  **5% Stockholders:** |  |  |
|  Rubric Capital Management LP<sup>(7)</sup> | 2946908 | 25.5% |
|  Clearline Capital LP<sup>(8)</sup> | 635222 | 5.5% |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents less than 1% of the outstanding shares of our common stock.

(1)&nbsp;&nbsp;&nbsp;&nbsp; Based on 11,574,362 shares outstanding as of October 20, 2025.

(2)&nbsp;&nbsp;&nbsp;&nbsp; Includes (i) 73,639 shares held by Mr. Walker directly, (ii) 1,733 shares issuable to Mr. Walker underlying vested but unsettled restricted stock units, (iii) 5,200 shares issuable to Mr. Walker underlying vested but unsettled performance stock units and (iv) 4,000 shares issuable to Mr. Walker upon the exercise of vested stock options.

(3)&nbsp;&nbsp;&nbsp;&nbsp; Includes (i) 14,312 shares held by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson, (ii) 14,779 shares held by Mr. Thompson directly, (iii) 21 shares held indirectly by Thompson Family Holdings, LLC and (iv) 7,250 shares issuable to Mr. Thompson upon the exercise of vested stock options.

(4)&nbsp;&nbsp;&nbsp;&nbsp; Includes (i) 60,516 shares held by Mr. Collins directly and (ii) 5,000 shares issuable to Mr. Collins upon the exercise of vested stock options.

(5)&nbsp;&nbsp;&nbsp;&nbsp; Includes 8,500 shares held by Dr. Naughton directly.

(6)&nbsp;&nbsp;&nbsp;&nbsp; Includes 7,500 shares held by Mr. Ziegler directly.

(7)&nbsp;&nbsp;&nbsp;&nbsp; Based solely on the Schedule 13D/A filed with the SEC by Rubric Capital Management LP on November 17, 2023. Rubric Capital Management LP has shared voting and shared dispositive power over 2,946,908 shares. The address of Rubric Capital Management LP is 155 East 44<sup>th</sup> Street, Suite 1630, New York, NY 10017.

(8)&nbsp;&nbsp;&nbsp;&nbsp; Based solely on a Schedule 13G filed with the SEC by Clearline Capital LP on February 12, 2025. Clearline Capital LP has shared voting and shared dispositive power over 635,222 shares. The address of Clearline Capital LP is 950 Third Avenue, 23<sup>rd</sup> Floor, New York, NY 10022.

&nbsp;&nbsp;&nbsp;&nbsp; 31 <br>

------

[**Table of Contents**](#TOC001)

### Proposal Two

### Advisory Vote on Executive Compensation ("Say-on-Pay")

#### Background
The Dodd-Frank Act enables our stockholders to vote to approve, on an advisory (non-binding) basis, the compensation of our NEOs as disclosed in this proxy statement in accordance with the SEC's rules.

#### Summary
Pursuant to Section 14A of the Exchange Act, we are asking our stockholders to provide advisory approval of the compensation of our NEOs, as such compensation is described in the "Executive Compensation" section of this proxy statement. Our executive compensation program is designed to enable us to attract, motivate, and retain highly qualified executives. This program provides long-term stock-based incentive compensation that focuses our executives' efforts on building stockholder value by aligning their interests with those of our stockholders. We urge our stockholders to review the executive-related compensation information and related tables for more information.

The say-on-pay vote is advisory, and therefore not binding on our Company, the Compensation Committee, or our Board of Directors. Although non-binding, the vote will provide information to the Compensation Committee and our Board of Directors regarding investor sentiment about our executive compensation philosophy, policies, and practices, which the Compensation Committee and our Board of Directors will be able to consider when determining executive compensation for the years to come.

It is expected that the next say-on-pay vote will occur at the 2026 annual meeting of stockholders.

#### Board Recommendation
Our Board of Directors believes that the information provided within the "Executive Compensation" section of this proxy statement demonstrates our executive compensation program is designed appropriately and is working to ensure our NEOs receive the majority of their compensation based on performance-driven considerations and that management's interests are aligned with our stockholders' interests to support long-term value creation.

The following resolution is submitted for a stockholder vote at the annual meeting:

**RESOLVED**, that the stockholders of the Company approve, on an advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2024, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion set forth in this proxy statement.

 **OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" ADOPTION OF THE RESOLUTION APPROVING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024, AS DESCRIBED IN THE EXECUTIVE COMPENSATION SECTION, INCLUDING THE TABULAR AND NARRATIVE DISCLOSURE SET FORTH IN THIS PROXY STATEMENT.**<br>

&nbsp;&nbsp;&nbsp;&nbsp; 32<br>

------

[**Table of Contents**](#TOC001)

### Proposal Three

### Advisory Vote on Determining the Frequency of Say-on-Pay ("Say-on-Frequency")

#### Background
The Dodd-Frank Act enables our stockholders to indicate how frequently they believe we should seek an advisory vote on the compensation of our NEOs. Stockholders have the option of recommending a frequency vote every year, every two years, or every three years or abstaining from making a recommendation.

#### Summary
Our Board of Directors has considered the advantages and disadvantages of the frequency of the say-on-pay vote. Based on its analysis, our Board of Directors believes that an annual advisory vote of on executive compensation would be the most meaningful for our Board of Directors and our Compensation Committee and best serve the interests of our company and its stockholders. Our Board of Directors believes an annual advisory vote will provide the most timely feedback on executive compensation arrangements, plans, programs, and policies as executive compensation disclosures are made annually.

Stockholders should recognize, however, it may not be appropriate or feasible to change compensation programs already in place for the year in which the vote occurs since the advisory vote on executive compensation will take place after the beginning of the compensation year. Stockholders also should recognize that their recommendation may be modified in the future if an annual frequency vote becomes burdensome or otherwise proves to be less helpful than originally expected.

We will consider stockholders to have expressed a preference for the frequency that receives the largest number of favorable votes. Our Board of Directors also may from time to time decide that it is in the best interests of our company and its stockholders to hold the frequency vote more or less frequently than the non-binding option preferred by our stockholders.

#### Board Recommendation
 **OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE<br>"ONE YEAR" ON THE PROPOSAL TO DETERMINE THE FREQUENCY OF SAY**-ON-PAY**.**<br>

&nbsp;&nbsp;&nbsp;&nbsp; 33 <br>

------

[**Table of Contents**](#TOC001)

### Proposal Four

### Ratification of Appointment of Independent Auditor
The Audit Committee of our Board of Directors has selected and appointed Berkowitz Pollack Brant as our independent registered public accounting firm for the 2025 fiscal year. Berkowitz Pollack Brant has served as our independent registered public accounting firm since July 7, 2023.

Our Audit Committee recommends that stockholders vote in favor of the ratification of the appointment of Berkowitz Pollack Brant to audit the consolidated financial statements of our Company for the fiscal year ending December 31, 2025. Although ratification is not required by our bylaws or otherwise, our Board of Directors is submitting the appointment of Berkowitz Pollack Brant to our stockholders for ratification as a matter of good corporate practice. In the event of a negative vote on such ratification, our Audit Committee will reconsider its selection.

We expect that representatives of Berkowitz Pollack Brant will be present at the annual meeting, will have the opportunity to make a statement if they desire to do so, and will be available to respond to appropriate questions.

#### Change in Independent Registered Public Accounting Firm
On July 7, 2023, the Audit Committee dismissed Grant Thornton LLP ("Grant Thornton") as the company's independent registered public accounting firm and engaged Berkowitz Pollack Brant as the Company's independent registered public accounting firm for the 2023 fiscal year. The decision to change the Company's independent registered public accounting firm was the result of a request for proposal process. Grant Thornton's reports on the Company's financial statements for each of the fiscal years ended December 31, 2022 and December 31, 2021 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that Grant Thornton's reports on the Company's financial statements as of and for the fiscal years ended December 31, 2022 and 2021 included an explanatory paragraph describing the uncertainty of the Company's ability to continue as a going concern. During the Company's fiscal years ended December 31, 2022 and December 31, 2021, and through the date of dismissal, there were no disagreements with Grant Thornton on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to the satisfaction of Grant Thornton, would have caused Grant Thornton to make reference to the subject matter of the disagreement in connection with its report. During the fiscal years ended December 31, 2022 and December 31, 2021 and the subsequent period through the date of dismissal, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S -K promulgated by the Securities and Exchange Commission (the "SEC"). During the fiscal years ended December 31, 2022 and December 31, 2021 and the subsequent period to the date of its engagement, neither the Company nor anyone acting on its behalf has consulted with Berkowitz Pollack Brant regarding (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report or oral advice was provided to the Company that Berkowitz Pollack Brant concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.

#### Principal Accountant Fees and Services
Berkowitz Pollack Brant acted as our independent registered public accounting firm for 2024 and a portion of 2023, and Grant Thornton acted as our independent registered public accounting firm for a portion of 2023.

Aggregate fees billed to our company for the fiscal year ended December 31, 2024 and 2023 by Berkowitz Pollack Brant, Advisors + CPAs were as follows:

---

| | | |
|:---|:---|:---|
|  | **2024 <br>($)** | **2023 <br>($)** |
|  Audit fees | 201345 | 186575 |
|  Audit-related fees |  |  |
|  Tax fees |  |  |
|  All other fees |  |  |
|  **Total** | 201345 | 186575 |

---

&nbsp;&nbsp;&nbsp;&nbsp; 34<br>

------

[**Table of Contents**](#TOC001)

Audit fees consist of fees associated with the annual audit, the reviews of our annual and quarterly reports, and other filings with the SEC as well as comfort letters and consents. Audit-Related Fees consist of fees for the audit of the financial statements of our former subsidiary vitaCare Prescription Services, Inc. Tax fees included the preparation of our tax returns and other related services. All Other Fees consist of fees associated with consulting and advisory services.

#### Audit Committee Pre-Approval Policies and Procedures
The charter of our Audit Committee provides that the duties and responsibilities of our Audit Committee include the pre-approval, or adopting procedures for pre-approval, of all audit, audit-related, tax, and other services permitted by law or applicable SEC regulations (including fee and cost ranges) to be performed by our independent auditor. Any pre-approved services that will involve fees or costs exceeding pre-approved levels will also require specific pre-approval by the Audit Committee. Unless otherwise specified by the Audit Committee in pre-approving a service, the pre-approval will be effective for the twelve (12)-month period following pre-approval. The Audit Committee will not approve any non-audit services prohibited by applicable SEC regulations or any services in connection with a transaction initially recommended by the independent auditor, the purpose of which may be tax avoidance and the tax treatment of which may not be supported by the Internal Revenue Code and related regulations.

To the extent deemed appropriate, the Audit Committee may delegate pre-approval authority to the Chairperson of the Audit Committee or any one or more other members of the Audit Committee provided that any member of the Audit Committee who has exercised any such delegation must report any such pre-approval decision to the Audit Committee at its next scheduled meeting. The Audit Committee will not delegate to management the pre-approval of services to be performed by the independent auditor.

Our Audit Committee requires that our independent auditor, in conjunction with our Principal Financial Officer, be responsible for seeking pre-approval for providing services to us and that any request for pre-approval must inform the Audit Committee about each service to be provided and must provide detail as to the particular service to be provided.

All of the services provided by our independent auditor described above were approved by our Audit Committee pursuant to our Audit Committee's pre-approval policies.

#### Ratification by Stockholders of the Appointment of Independent Auditor
Ratification of the appointment of Berkowitz Pollack Brant to audit the consolidated financial statements of our Company for the fiscal year ending December 31, 2025 will require the affirmative vote of a majority of the votes cast, assuming that a quorum is present at the meeting.

#### Board Recommendation
 **OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" THE RATIFICATION OF BERKOWITZ POLLACK BRANT ADVISORS + CPAS, LLP TO AUDIT THE CONSOLIDATED FINANCIAL STATEMENTS OF OUR COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.**<br>

&nbsp;&nbsp;&nbsp;&nbsp; 35 <br>

------

[**Table of Contents**](#TOC001)

### Proposal Five

### Approval of an Amendment to the Amended and Restated Articles of Incorporation

#### Background
Our Board of Directors has approved the amendment to our Amended and Restated Articles of Incorporation, as amended, subject to stockholder approval, to increase the number of authorized shares of common stock from 32,000,000 shares to 640,000,000 shares (the "Share Increase") and recommends unanimously that our stockholders approve the Share Increase. The proposed amendment is reflected in the Charter Amendment attached to this proxy statement as **<u>Appendix A</u>**. For avoidance of doubt, this Proposal Five will only amend Article IV of our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock to 640,000,000. You are encouraged to read the Charter Amendment in its entirety.

The additional 608,000,000 shares of common stock will be part of the existing class of common stock and, if and when issued, would have the same rights and privileges as the shares of common stock presently issued and outstanding. The Company's Amended and Restated Articles of Incorporation, as amended, have not been amended to increase the number of authorized shares of common stock since June 2023.

#### Purpose
Our Board of Directors believes that the authorized number of shares of common stock should be increased as a matter of good corporate governance to provide sufficient shares for such corporate purposes as may reasonably be determined by the Board of Directors to be necessary and in the best interest of our Company and stockholders. These purposes may include, but are not limited to:

• raising capital through the future sale of our common stock when necessary or appropriate;

• expanding our business through the acquisition of other businesses, products, or assets; and

• establishing partnerships, collaborations, and/or other strategic relationships with other companies.

Our Board of Directors believes that these additional shares would provide us with needed flexibility to issue shares in the future without potential expense or delay incident to obtaining stockholder approval for a particular issuance. We do not have any specific plans, arrangements, undertakings or agreements for the proposed increase of authorized shares in connection with any of the foregoing prospective activities. Once authorized, the additional shares of common stock may be issued with approval of our Board of Directors but without further approval from our stockholders, unless applicable law, rule or regulation requires stockholder approval for such issuance. Stockholder approval of the Share Increase is required under Nevada law.

#### Proposed Changes to the Amended and Restated Articles of Incorporation, as Amended
The proposed Share Increase will increase the number of shares of common stock authorized for issuance from 32,000,000 shares to 640,000,000 shares. The Company is currently authorized to issue 42,000,000 shares of capital stock, of which 32,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock, $0.001 par value per share (none of which are currently issued and outstanding). The Share Increase will not change any substantive terms of the common stock or preferred stock or any powers or rights of their respective holders. The common stock will continue to be listed and traded on the Nasdaq Global Select Market under the symbol "TXMD."

If Proposal Five is approved, we intend to amend our Amended and Restated Articles of Incorporation, as amended, in connection with implementing the proposal. A copy of the Charter Amendment is attached to this proxy statement as **<u>Appendix A</u>**.

#### Certain Risks Associated with the Charter Amendment
There can be no assurance that the market price per share of our common stock after the Charter Amendment will remain constant.

The market price of our common stock will also be based on our performance and other factors, some of which are unrelated to the number of shares outstanding. These factors include the status of the market for our common stock, our reported results of operations in future periods, and general economic, market and industry conditions.

&nbsp;&nbsp;&nbsp;&nbsp; 36<br>

------

[**Table of Contents**](#TOC001)

#### Principal Effects on Outstanding Common Stock
Holders of common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. Upon a liquidation, dissolution or windup of our Company, holders of common stock would be entitled to share ratably in any assets for distribution to stockholders after payment of all of the Company's obligations, subject to the rights to receive preferential distributions of the holders of any preferred stock then outstanding.

The additional shares of common stock would have rights identical to our common stock currently outstanding. Approval of the Share Increase and any issuance of common stock would not affect the rights of the holders of our common stock currently outstanding, except to the extent that future issuances of common stock would reduce each existing stockholder's proportionate ownership. If the proposed Share Increase is approved and the Board of Directors decides to issue such shares of common stock, such issuance of common stock would increase the outstanding number of shares of common stock, thereby causing dilution in earnings per share and voting interests of the outstanding common stock. As of the record date, 11,574,362 shares of our common stock were issued and outstanding, 149,074 shares of our common stock were subject to outstanding stock options, warrants, restricted stock awards, or other convertible securities, and 51,030 shares of our common stock were reserved for issuance under the 2019 Plan, thereby leaving 20,225,534 shares of common stock unassigned and authorized for potential issuance of the current 32,000,000 shares of common stock authorized. If approved, the Share Increase will not change the number of shares of preferred stock authorized for issuance.

Additionally, the issuance of additional shares of common stock could have the effect of making it more difficult for a third party to acquire, or discouraging a third party from attempting to acquire, control of our Company. While the issuance of additional shares of common stock may be deemed to have potential anti-takeover effects, including by delaying or preventing a change in control of the Company through subsequent issuances of these shares and the other reasons set forth above, which among other things, could include issuances in one or more transactions that would make a change in control of the Company more difficult, and therefore, less likely, this proposal to increase the authorized common stock is not prompted by any specific effort of which we are aware to accumulate shares of our common stock or obtain control of the Company. A takeover may be beneficial to independent stockholders because, among other reasons, a potential suitor may offer such stockholders a premium for their shares of common stock as compared to the then-existing market price. Although the issuance of additional shares of common stock could, under certain circumstances, have an anti-takeover effect, this proposal to adopt the Charter Amendment is not in response to any attempt to accumulate common stock or obtain control of the Company that we are aware of, nor is it part of a plan by management to recommend a series of similar amendments to the Board of Directors or stockholders.

#### Effectiveness of the Proposed Amendment
If the Charter Amendment is approved by our stockholders at the annual meeting, then, promptly following the annual meeting, we intend to file the Certificate of Amendment to Articles of Incorporation with the Secretary of State of the State of Nevada attached to this proxy statement as **<u>Appendix A</u>**, which will become effective upon filing. The Board of Directors retains the discretion to abandon and not implement the Charter Amendment at any time before it becomes effective.

#### Board Recommendation
 **OUR BOARD OF DIRECTORS HAS UNANIMOUSLY DETERMINED THAT APPROVAL OF THE CHARTER AMENDMENT IS IN THE BEST INTERESTS OF THE COMPANY AND ITS STOCKHOLDERS. ON THE BASIS OF THE FOREGOING, OUR BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED THE CHARTER AMENDMENT AND UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" THE APPROVAL OF THE CHARTER AMENDMENT.**<br>

&nbsp;&nbsp;&nbsp;&nbsp; 37 <br>

------

[**Table of Contents**](#TOC001)

### DEADLINE FOR RECEIPT OF STOCKHOLDER PROPOSALS
As more specifically provided in our bylaws, as amended, no business may be brought before an annual meeting of stockholders unless it is specified in the notice of the meeting or is otherwise properly brought before the meeting by or at the direction of our Board of Directors or by a stockholder entitled to vote who has delivered proper notice to us, together with the information required by our bylaws, as amended. Director nominations and stockholder proposals that are intended to be presented by stockholders at the annual meeting of stockholders for the fiscal year ending December 31, 2025 must be received by us not less than 90 days (by September 16, 2026) and not more than 120 days (by August 17, 2026) before the anniversary of the prior year's annual meeting of stockholders, unless we change the date of our 2026 annual meeting by more than 30 days before or 60 days after such anniversary date, in which case, stockholder proposals must be received not earlier than 120 days prior to the annual meeting and not later than the later to occur of 90 days prior to the annual meeting and ten days following the date on which a public announcement of the date of the annual meeting is first made by us.

Stockholders interested in submitting a proposal for inclusion in our proxy materials for the 2026 annual meeting may do so by following the procedures set forth in Rule 14a-8 under the Exchange Act and our bylaws, as amended. To be eligible for inclusion in such proxy materials, stockholder proposals must be received not later than July 6, 2026.

In addition to satisfying the requirements regarding director nominations in our bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19(b) under the Exchange Act no later than October 16, 2026.

Stockholder proposals should be addressed and delivered to our corporate secretary at the address of our executive offices set forth in this proxy statement.

### HOUSEHOLDING OF PROXY MATERIALS
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for annual reports, proxy statements, and Notices of Internet Availability of Proxy Materials with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as "householding," potentially means extra convenience for stockholders and cost savings for companies.

If you and other stockholders of record with whom you share an address currently receive multiple copies of our annual report, proxy statement, or Notice of Internet Availability of Proxy Materials and would like to participate in our householding program, please contact our transfer agent, Computershare Trust Company, N.A., by calling toll-free at 800-962-4284, or by writing to Computershare, P.O. Box 43006, Providence, Rhode Island 02940-3006. Alternatively, if you participate in householding and wish to revoke your consent and receive separate copies of our annual report, proxy statement, or Notice of Internet Availability of Proxy Materials, please contact Computershare as described above. In addition, we will promptly deliver, upon the written or oral request to Computershare at the address or telephone number above, a separate copy of our annual report, proxy statement, or Notice of Internet Availability of Proxy Materials to a stockholder at a shared address to which a single copy of the documents was delivered.

A number of brokerage firms have instituted householding. If you hold your shares in street name, please contact your bank, broker or other holder of record to request information about householding.

### OTHER MATTERS
We know of no other matters to be submitted at the meeting. If any other matters properly come before the meeting, it is the intention of the persons named in the enclosed proxy card to vote the shares they represent as our Board of Directors may recommend.

&nbsp;&nbsp;&nbsp;&nbsp; 38<br>

------

[**Table of Contents**](#TOC001)

### WHERE YOU CAN FIND ADDITIONAL INFORMATION AND INCORPORATION BY REFERENCE
We are subject to the informational requirements of the Exchange Act, and are required to file reports, any proxy statements and other information with the SEC. Copies of any reports, statements or other information that we file with the SEC, including this proxy statement, can also be obtained upon written request or from the SEC's website on the Internet at www.sec.gov, free of charge. We also maintain a website at www.therapeuticsmd.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.

We have not authorized anyone to provide you with information that differs from that contained in this proxy statement. You should not assume that the information contained in this proxy statement is accurate as on any date other than the date of the proxy statement, and the mailing of this proxy statement to our stockholders shall not create any implication to the contrary.

This proxy statement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction to or from any person to whom it is not lawful to make any such offer or solicitation in such jurisdiction.

This proxy statement incorporates by reference our Annual Report on Form 10-K for the year ended December 31, 2024 that we previously filed with the SEC; provided, however, that we are not incorporating by reference Part III thereof and any documents, portions of documents or information deemed to have been furnished and not filed in accordance with SEC rules.

In addition, we are incorporating by reference herein any future filings we make with the SEC under Section 11, 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this proxy statement and prior to the date of the annual meeting. Such documents are considered to be a part of this proxy statement, effective as of the date such documents are filed. In the event of conflicting information in these documents, the information in the latest filed document should be considered correct.

You can obtain any of the documents listed above from the SEC, through the website of the SEC at the address described above or from us by requesting them in writing or by telephone at the following address:

TherapeuticsMD, Inc.

Attention: Corporate Secretary

951 Yamato Road, Suite 220

Boca Raton, Florida 33431

(561) 961-1900

&nbsp;&nbsp;&nbsp;&nbsp; 39 <br>

------

[**Table of Contents**](#TOC001)

**<u>Appendix A</u>**

**Amendment to the Amended and Restated Articles of Incorporation, as Amended**

&nbsp;&nbsp;&nbsp;&nbsp; A-1 <br>

------

[**Table of Contents**](#TOC001)

![](timage_004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp; A-2<br>

------

[**Table of Contents**](#TOC001)

![](timage_005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp; A-3 <br>

------

[**Table of Contents**](#TOC001)

![](tproxy_001.jpg)

Copyright© 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved The undersigned hereby appoints Marlan Walker and Joseph Ziegler (the "Named Proxies"), and each or either of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of capital stock of TherapeuticsMD, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors' recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. This proxy is being solicited on behalf of the Board of Directors PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE TherapeuticsMD, Inc. Annual Meeting of Stockholders For Stockholders of Record as of October 20, 2025 Monday, December 15, 2025 8:00 AM, Eastern Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/TXMD for more details. C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Internet: www.proxypush.com/TXMD Cast your vote online Have your Proxy Card ready Follow the simple instructions to record your vote Phone: 1-866-474-8637 Use any touch-tone telephone Have your Proxy Card ready Follow the simple recorded instructions Mail: Mark, sign and date your Proxy Card Fold and return your Proxy Card in the postage-paid envelope provided Virtual: You must register to attend the meeting online and/or participate at www.proxydocs.com/TXMD YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: 8:00 AM, Eastern Time, December 15, 2025. Have your ballot ready and please use one of the methods below for easy voting: Your vote matters! Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

------

[**Table of Contents**](#TOC001)

![](tproxy_002.jpg)

TherapeuticsMD, Inc. Annual Meeting of Stockholders Please make your marks like this: THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 4 AND 5 THE BOARD RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR. PROPOSAL YOUR VOTE BOARD OF DIRECTORS RECOMMENDS 1. To elect directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; FOR WITHHOLD 1.01 Tommy G. Thompson FOR 1.02 Cooper C. Collins FOR 1.03 Gail K. Naughton, Ph.D. FOR 1.04 Justin Roberts FOR 2. To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2024; FOR 1YR 2YR 3YR ABSTAIN 3. To provide a non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our named executive officers; 1 YEAR FOR AGAINST ABSTAIN 4. To ratify the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP, an independent registered public accounting firm, as the independent auditor of our Company for the fiscal year ending December 31, 2025; FOR 5. To approve an amendment to our Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, to 640,000,000 shares; FOR 6. To transact such other business as may properly come before the meeting or any adjournment thereof. FOR AGAINST ABSTAIN You must register to attend the meeting online and/or participate at www.proxydocs.com/TXMD Authorized Signatures - Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date

------